Different cannabis compounds work best for different chronic pain types

Assessing the Efficacy of Cannabinoid Compositions for Treating 3 Classes of Chronic Pain: A Real-World Evidence Study.

Clinical therapeutics • • Moderately Relevant
🤖

AI Summary

This real-world evidence study examined how different combinations of cannabis compounds work for treating three major types of chronic pain: fibromyalgia, rheumatoid arthritis, and knee/hip osteoarthritis. Researchers gave 164 California residents one of three cannabinoid formulations for 12 weeks—one with CBD and THC, another with raw cannabinoid acids (THCA, CBDa, and others), and a third with just CBD and CBDa. The results were encouraging: participants experienced significant improvements in pain, anxiety, sleep quality, and physical functioning across all three pain conditions, with effect sizes ranging from small to large.

The study revealed important differences in how specific cannabinoid combinations work. Product 2 (containing cannabinoid acids) was particularly effective at reducing neuropathic pain, while the three products showed different effectiveness for sleep disturbance—highlighting that cannabinoid composition matters for specific symptoms. Notably, nonintoxicating compounds like CBD and CBDa provided substantial relief without the high associated with THC, offering an important option for patients who need pain management without psychoactive effects.

These findings suggest that cannabis patients have multiple viable options depending on their specific pain type and whether they want intoxicating effects. The study strengthens evidence that various cannabinoid combinations—not just THC alone—can effectively treat chronic pain, and that cannabinoid acids like THCA and CBDa deserve more research attention as therapeutic agents.

📄 Original Abstract

Cannabis has been determined to be effective at treating chronic pain, although research on the effects of specific cannabinoids, especially for different mechanisms of chronic pain, is limited. This study examined therapeutic efficacy for combinations of intoxicating and nonintoxicating cannabinoids for symptoms of 3 different types of chronic pain conditions. We recruited adult California residents diagnosed with fibromyalgia (n = 64), rheumatoid arthritis (n = 25), and osteoarthritis of the knee and/or hip (n = 75). Participants in each group were randomly assigned to receive a 12-week supply of oral capsules with 3 different cannabinoid compositions: product 1-12.5 mg cannabidiol (CBD) and 12.5 mg tetrahydrocannabinol (n = 45); product 2-10 mg tetrahydrocannabinolic acid, 10 mg cannabidiolic acid (CBDa), 5 mg cannabigerol, and 3 mg cannabichromene (n = 57); and product 3-10 mg CBD and 10 mg CBDa (n = 62). Participants completed validated self-report questionnaires assessing pain characteristics, mental health and cognitive functioning, and physical functioning at baseline and 12-week timepoints. Of 276 individuals recruited, 168 (60.9%) completed all survey questionnaires. Four individuals who completed the questionnaires but discontinued study product use were removed from the dataset. Per-protocol analyses identified significant improvements across all symptoms except cognitive function abilities. Effects ranged from small to large; most did not differ in magnitude across product or type of chronic pain. Products differed in effectiveness for sleep disturbance, and participants taking product 2 reported reductions in neuropathic pain intensity. These findings suggest that various cannabinoid combinations may have beneficial effects across 3 different types of chronic pain. Nonintoxicating cannabinoids such as CBD and CBDa may provide relief from pain and related symptoms and may be utilized when cannabis intoxication is undesirable or problematic.

Explore More Research

Stay informed about the latest cannabis science.

Your stash, decoded.